Surgery Partners' high P/S ratio, despite industry-standard revenue forecasts, could risk shareholders' investments and potential investors may pay an unnecessary premium. This may be due to bullish sentiment, which could lead to disappointment if the P/S falls in line with the growth outlook.
Surgery Partners股票讨论
• $Arcos Dorados(ARCO.US)$ : Bradesco BBI 从 “中性” 上调至 “跑赢大盘” ——PT $12
• $阿姆斯特朗工业(AWI.US)$ : Loop Capital升级为持有买入——PT $95
• $库伦佛寺银行(CFR.US)$ : 摩根大通从减持上调至增持——155美元(从143美元起)
• $数字房地产信托公司(DLR.US)$ : 德意志银行上调至持有买入——144加元(从150美元起)
• $Liberty Formula One-A(FWONA.US)$ : 更多...
暂无评论